CeriBell (NASDAQ:CBLL) Trading 5.7% Higher - What's Next?

CeriBell (NASDAQ:CBLL - Get Free Report) shot up 5.7% during mid-day trading on Friday . The stock traded as high as $24.35 and last traded at $24.42. 92,156 shares were traded during mid-day trading, a decline of 45% from the average session volume of 166,898 shares. The stock had previously closed at $23.11.

Wall Street Analyst Weigh In

Several research firms have issued reports on CBLL. JPMorgan Chase & Co. began coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an "overweight" rating and a $32.00 price target on the stock. TD Cowen lifted their price target on shares of CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Canaccord Genuity Group began coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a "buy" rating and a $30.00 price target on the stock. Canaccord Genuity Group lifted their price target on shares of CeriBell from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Finally, William Blair initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an "outperform" rating on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $32.60.

CeriBell Trading Up 6.8 %

The company's fifty day simple moving average is $23.53.

Institutional Investors Weigh In On CeriBell

A number of large investors have recently made changes to their positions in CBLL. FMR LLC acquired a new position in CeriBell during the fourth quarter valued at $128,120,000. Corebridge Financial Inc. acquired a new position in CeriBell during the fourth quarter valued at $158,000. Board of Trustees of The Leland Stanford Junior University acquired a new position in CeriBell during the fourth quarter valued at $16,143,000. Norges Bank acquired a new position in CeriBell during the fourth quarter valued at $422,000. Finally, Next Century Growth Investors LLC acquired a new position in shares of CeriBell in the fourth quarter worth about $5,299,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.